TGFB1 and bone cancer: In osteosarcoma, 24 h treatment with low concentrations of oridonin (0.5–2 μM) decreased the migration and invasion capabilities of 143B and MG-63 bone cancer cells by significantly inhibiting the phosphorylation of TGF-β and preventing the Smad dimer from translocating into the nucleus [54].